Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06506422 · ClinicalTrials.gov registry record · Phase 2
Empagliflozin Reversal of Arterial StiffnEss in Aging
A Phase 2 study of Aging and Arterial Stiffness, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06506422 is a Phase 2 study of Aging and Arterial Stiffness that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 80 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06506422, a Phase 2 study of Aging and Arterial Stiffness, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin 10 MG
Study Locations (1)
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-08-18 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06506422
The ClinicalTrials.gov registry entry for NCT06506422 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (96% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06506422 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06506422 about?
NCT06506422 is a clinical study titled "Empagliflozin Reversal of Arterial StiffnEss in Aging". Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
What is the current status of trial NCT06506422?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-08-18. Estimated completion is 2029-02-28.
What conditions does trial NCT06506422 study?
This clinical trial studies the following conditions: Aging, Arterial Stiffness.
What interventions are being tested in trial NCT06506422?
The interventions under investigation include: Placebo (DRUG), Empagliflozin 10 MG (DRUG).
Who is sponsoring clinical trial NCT06506422?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06506422 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
Acetate and Age-associated Arterial Dysfunction
RECRUITING · Phase 2
-
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
RECRUITING · Phase 2
-
Fisetin to Reduce Senescence and Mobility Impairment in PAD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.